AmeraCell Revolutionizes Cellular Health with Breakthrough Treatment Combining NAD+ and MSC
United States, 26th Mar 2025 – AmeraCell, a pioneering regenerative medicine company, is proud to announce a groundbreaking new treatment that harnesses the synergistic power of Nicotinamide Adenine Dinucleotide (NAD+) and Mesenchymal Stem Cells (MSC) to promote cellular health and combat inflammation.
This innovative therapy, available exclusively at AmeraCell, leverages the unique properties of NAD+ and MSC to restore cellular balance, enhance energy metabolism, and mitigate the effects of chronic inflammation.
“NAD+ and MSC are two of the most promising tools in the fight against aging and disease,” said AJ Pakpour, Founder and CEO of AmeraCell. “By combining these two powerful agents, we’ve created a revolutionary treatment that has the potential to transform the lives of millions.”
NA...